Research programme: antifungals - Aurigene/Pcovery
Latest Information Update: 23 Apr 2014
At a glance
- Originator Pcovery
- Developer Aurigene Discovery Technologies; Pcovery
- Mechanism of Action Membrane protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mycoses
Most Recent Events
- 23 Apr 2014 Research programme is ongoing in Denmark
- 09 Sep 2010 Early research in Mycoses in Denmark (unspecified route)